Johnson & Johnson's Resilience Makes It A Top Recession Pick

8/5/19

By Robert & Sam Kovacs, SeekingAlpha

Summary

  • Many recession-proof dividend stocks have done very well this year.
  • Yet Johnson & Johnson's stock price has been grounded because of litigation risk.
  • Investors will have to weigh the pros and cons of ongoing litigation, yet the stock remains a high-quality name.
  • The stock is trading around fair value, and will most likely beat the market during the next recession.
  • Written by Sam Kovacs

Introduction

When we think of recession-proof stocks, we think of two things: recession-resilient sectors (utilities, consumer staples, healthcare) and stocks that have been paying their dividend for a very long time.

A good shortcut would be to look at a list of dividend aristocrats within these sectors. It is no surprise that in that list we would see an all-time dividend investor favorite Johnson & Johnson (JNJ).

Source: Public Domain

During the last recession JNJ’s share price declined by 30% against the market’s 56%.

The stock is only one of two stocks (Microsoft (NASDAQ:MSFT) being the other) that has an AAA rating.

It is one of the stocks investors naturally think of when they contemplate recession-proof stocks. Other stocks that come to mind include Procter & Gamble (PG), Coca Cola (KO), Hormel Foods (HRL), Exxon (XOM), Chevron (CVX), Pepsi (PEP), Walmart (WMT) and 3M (MMM).

And while most of these safe stocks have done very well year to date, JNJ’s price has remained flat.

Litigation risk concerning opioids and talc proceedings have clearly inhibited the stock from trading any higher.

Despite the very real litigation risk, I believe JNJ remains your best bet for exposure to the healthcare sector.

Johnson & Johnson has a dividend yield of 2.92% & trades at $130.22. Based on my M.A.D Assessment JNJ has a Dividend Strength score of 89 and a Stock Strength score of 72.

This article will present and discuss the factors which show why I believe dividend investors should hold JNJ, and even consider initiating a position if they lack exposure to healthcare.

Source: mad-dividends.com

This article will first analyze JNJ’s potential as an income-producing investment before considering its potential for capital appreciation.

READ FULL ARTICLE HERE